Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Zollinger-Ellison Syndrome 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Paraganglioma 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoid Tumor 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

lutetium Lu 177 dotatate 2Sunitinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Everolimus 2sargramostim 1sapanisertib 1pentetreotide 1pasireotide 1napabucasin 1montanide ISA 51 1irinotecan sucrosofate 1incomplete Freund's adjuvant 1fludarabine phosphate 1aflibercept 1Taxes 1Sorafenib 1Salts 1Paclitaxel 1Oxaliplatin 1Octreotide 1Leucovorin 1Irinotecan 1Interleukin-13 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenoma, Islet Cell × Octreotide × Clear all
NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 1 Completed
19 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡